Activités biologiques des extraits de Psychotriabridsoniae A. Davis & Govaerts (Rubiaceae) de Madagascar Lalasoa Ranaivoarison Ranarivelo(1), Tiana Sylvia Rasoarivelo Ralambonirina(1), Oliva Jaconnet Andrianaivoravelona(2), Henintsoa Harizafy(2), Faliarivony Randriamialinoro(1), Stéphan Rakotonandrasana(1), Andriamalala Rakotondrafara(1), Edouard Ravalison Andrianarison(3), Marylin Lecsö(4),
Efns guidelines on the clinical management of amyotrophic lateral sclerosis (mals) revised report of an efns task forceEuropean Journal of Neurology 2012, 19: 360–375 EFNS guidelines on the Clinical Management of AmyotrophicLateral Sclerosis (MALS) – revised report of an EFNS task force The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis: Peter M.
Andersena, Sharon Abrahamsb, Gian D. Borasioc, Mamede de Carvalhod, Adriano Chioe, PhilipVan Dammef, Orla Hardimang, Katja Kolleweh, Karen E. Morrisoni, Susanne Petrih,Pierre-Francois Pradatj, Vincenzo Silanik, Barbara Tomikl, Maria Wasnerm and Markus WebernaUmea˚ University, Umea˚, Sweden; bUniversity of Edinburgh, Edinburgh, UK; cCentre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland; dHospital de Santa Maria, Lisbon, Portugal; eUniversity of Turin and San Giovanni Hospital, Turin, Italy;fUniversity of Leuven and VIB, Leuven, Belgium; gTrinity College and Beaumont Hospital, Dublin, Ireland; hMedizinische Hochschule Hannover, Germany; iSchool of Clinical and Experimental Medicine, University of Birmingham and Queen Elizabeth Hospital, Birmingham, UK;jHoˆpital de la Salpeˆtrie re, Paris, France; kUniversity of Milan Medical School, Milan, Italy; lJagiellonian University Medical College, Krakow, Poland; mMunich University Hospital, Munich, Germany; and nKantonsspital St Gallen and University Hospital Basel, Basel, Switzerland Background: The evidence base for the diagnosis and management of amyotrophic ALS, breaking the lateral sclerosis (ALS) is weak.
diagnosis, bronchial Objectives: To provide evidence-based or expert recommendations for the diagnosis secretions, caregiver, and management of ALS based on a literature search and the consensus of an expert cognitive dysfunction, drooling, Evidence-based Methods: All available medical reference systems were searched, and original papers, medicine, genetic meta-analyses, review papers, book chapters and guidelines recommendations were counselling, nutrition, reviewed. The ﬁnal literature search was performed in February 2011. Recommen- palliative care, terminal dations were reached by consensus.
care, ventilation Recommendations: Patients with symptoms suggestive of ALS should be assessed assoon as possible by an experienced neurologist. Early diagnosis should be pursued, Received 16 November 2010 and investigations, including neurophysiology, performed with a high priority. The Accepted 12 July 2011 patient should be informed of the diagnosis by a consultant with a good knowledge ofthe patient and the disease. Following diagnosis, the patient and relatives/carersshould receive regular support from a multidisciplinary care team. Medication withriluzole should be initiated as early as possible. Control of symptoms such assialorrhoea, thick mucus, emotional lability, cramps, spasticity and pain should beattempted. Percutaneous endoscopic gastrostomy feeding improves nutrition andquality of life, and gastrostomy tubes should be placed before respiratory insuﬃciencydevelops. Non-invasive positive-pressure ventilation also improves survival andquality of life. Maintaining the patientÕs ability to communicate is essential. Duringthe entire course of the disease, every eﬀort should be made to maintain patientautonomy. Advance directives for palliative end-of-life care should be discussed earlywith the patient and carers, respecting the patientÕs social and cultural background.
warrant an updating of the 2005 EFNS guidelines  with the primary aim of establishing evidence-based This systematic review is an objective appraisal of the and patient- and carer-centred guidelines for diagnosing evidence regarding the diagnosis and clinical manage- and managing patients with ALS for clinicians, with the ment of patients with amyotrophic lateral sclerosis secondary aim of identifying areas where further (ALS). Advances in the knowledge and care of ALS research is needed.
Correspondence: Peter Munch Andersen, Professor of Neurology, Institute of Clinical Neuroscience, Umea˚ University, SE-901 85 Umea˚, Amyotrophic lateral sclerosis is characterized by Sweden (tel.: +46 90 7852372; fax: +46 90 14 31 07; e-mail:[email protected]).
symptoms and signs of degeneration of the upper and Ó 2011 The Author(s) European Journal of Neurology Ó 2011 EFNS EFNS Task Force on Management of ALS lower motor neurons, leading to progressive weakness resulting in level A, B or C recommendations . Where of the bulbar, limb, thoracic and abdominal muscles.
there was lack of evidence but consensus was clear, we Other brain functions, including oculomotor and have stated our opinion as Good Clinical Practice sphincter function, are relatively spared, but may be Points (GCPP).
involved in some patients. Cognitive dysfunction occursin 20–50% of cases, and 5–15% develop dementia usually of frontotemporal type. Death because ofrespiratory failure follows on average 2–4 years after Diagnosing ALS is usually straightforward if the patient symptom onset, but 5–10% of patients may survive for has progressive, generalized symptoms in the bulbar and a decade or more . The mean age of onset is 43– limb regions (Table 1) . Diagnosis early in the course 52 years in familial and 58–63 years in sporadic cases of of the disease when the patient has symptoms limited to ALS . The life-time risk of developing ALS is 1 in one or two regions (bulbar, upper limb, trunk, lower 350–500, with male sex, increasing age and hereditary limb) may be diﬃcult and depends on the presence of disposition being the main risk factors [3–5].
signs in other regions and supportive ﬁndings in ancill-iary investigations [7–9] (class IV). The mean time fromthe onset of symptoms to conﬁrmation of the diagnosis of ALS is 10–18 months [10,11] (class IV). Delays may From 2008 through February 2011, we searched the arise if early or intermittent symptoms are unrecognized or denied by the patient, or because of ineﬃcient referral (CENTRAL) (The Cochrane Library to date); MED- pathways to a neurologist. There are cogent reasons for LINE-OVID (January 1966 on); MEDLINE-ProQuest; making the diagnosis as early as possible . Psycho- MEDLINE-EIFL; EMBASE-OVID (January 1990 logically, the absence of a deﬁnitive diagnosis, even of a on); the Science Citation Index (ISI); the National disorder carrying a poor prognosis, causes distress and Research Register; the Oxford Centre for Evidence- anxiety. Early diagnosis may obviate onerous and based Medicine; the American Speech Language potentially expensive tours of the healthcare system and Hearing Association (ASHA); the World Federation of facilitate future planning. Early diagnosis may also Neurology ALS page of reviews of published research; provide opportunities for treatment with neuroprotec- the Oxford Textbook of Palliative Medicine, the UK tive agents at a time when fewer cells are irreversibly Department of Health National Research Register compromised. Studies in experimental animal models and humans with SOD1 gene mutations indicate that AtoZ/DH_4002357) and national neurological data- the loss of motor neurons is preceded by a period of cellular dysfunction  which may be reversible.
ac.uk/). There were no constraints based on language or Our objective is to present guidelines for making the publication status. Conﬂicts of interest were disclosed.
correct diagnosis as early as possible. As no single Panellists were not compensated.
investigation is speciﬁc for ALS, and there is no Table 1 Diagnostic criteria for ALS Method for reaching consensus The diagnosis of ALS requires the presence of: (positive criteria) Initially, two investigators performed an independent Lower motor neuron signs (including EMG features in clinically literature search for each of 13 subjects addressed. Each unaffected muscles) pair of investigators prepared a written analysis that Upper motor neuron signs was communicated and discussed by email with the Progression of symptoms and signs The diagnosis of ALS requires the absence of (diagnosis by exclusion): other members of the task force. A combined draft was then written by the chairman and circulated to the task Sphincter disturbances force for further discussions. All recommendations had Visual disturbances to be agreed to by all members of the task force Autonomic features Basal ganglion dysfunctionAlzheimer-type dementiaALS ÔmimicÕ syndromes (Table 3) The diagnosis of ALS is supported by: Fasciculations in one or more regions The literature concerning 13 issues in the management Neurogenic changes in EMG results of ALS was evaluated by the task force. The ﬁndings Normal motor and sensory nerve conductionAbsence of conduction block were evaluated according to the recommendations ofthe European Federation of Neurological Societies ALS, amyotrophic lateral sclerosis; EMG, electromyography.
Ó 2011 The Author(s)European Journal of Neurology Ó 2011 EFNS European Journal of Neurology P. M. Andersen et al.
Table 2 Diagnosing amyotrophic lateral sclerosis/motor neuron disease: recommended investigations in selected cases Clinical chemistryBlood Erythrocyte sedimentation rate C-reactive protein Haematological screen ASAT, ALAT, lactate dehydrogenase Thyroid-stimulating hormone, free T4, free T3 hormone assays Vitamin B12 and folate Serum protein electrophoresis Electrolytes (Na+, K+, Cl), Ca2+, HPO2 ) Hexoaminidase A and B assay Ganglioside GM-1 antibodies Anti-Hu, anti-MAG RA, antinuclear antibodies, anti-DNA Anti-acetylcholine receptor and anti-muscle-speciﬁc receptor tyrosine kinase antibodies Serology (Borrelia, virus including HIV) DNA analysis (for SOD1, SMN, SBMA, TDP43, FUS) Total protein concentration Protein electrophoresis including IgG index Serology (Borrelia, virus) Ganglioside antibodies Lead (24-h secretion) Nerve conduction velocity Magnetic resonance imaging/computed tomography (cranial/cervical, thoracic, lumbar) sensitive and speciﬁc disease biomarker, diagnosis is Great care should be taken to rule out diseases that based on symptoms, clinical examination ﬁndings and can masquerade as ALS (Table 3) [15,16]. In specialist the results of electrodiagnostic, neuroimaging and lab- practice, 5–8% of apparent patients with ALS have an oratory studies (Tables 1 and 2) .
alternative diagnosis, which may be treatable in up to Ó 2011 The Author(s) European Journal of Neurology Ó 2011 EFNS European Journal of Neurology EFNS Task Force on Management of ALS Table 3 Diseases that can masquerade as ALS.
Table 3 (Continued) Anatomical abnormalities/compression syndromes ÔStiff person plusÕ syndromes Arnold–Chiari type 1 and other hindbrain malformations Cervical, foraman magnum or posterior fossa region tumours Electric shock neuronopathy Cervical disc herniation with osteochondrosis Cervical meningeoma Vascular disorders Retropharyngeal tumour Spinal epidural cyst DejerineÕs anterior bulbar artery syndrome Spondylotic myelopathy and/or motor radiculopathy Acquired enzyme defects Other neurological conditions Adult GM2 gangliosidosis (hexosaminidase A or B deﬁciency) Western Paciﬁc atypical forms of MND/ALS (Guam, New Guinea, Polyglucosan body disease Kii Peninsula of Japan) PompeÕs Disease (Glycogen Storage Disease type II) Carribean atypical forms of MND–dementia–PSP (Guadeloupe) Autoimmune syndromes Madras-form of juvenile onset MND/ALS (South India) Monoclonal gammopathy with motor neuropathy Frontotemporal dementia with MND/ALS (including PickÕs Multifocal motor neuropathy with/without conduction block disease with amyotrophy) Dysimmune lower motor neuron syndromes (with GM1, GD1b Multiple system atrophy and asialo-GM1 antibodies) Olivo-ponto cerebellar atrophy syndromes Other dysimmune lower motor neuron syndromes, including CIDP Primary lateral sclerosis (some subtypes not related to ALS) Multiple sclerosis Progressive encephalomyelitis with rigidity Myasthenia gravis (in particular the anti-muscle-speciﬁc receptor tyrosine kinase positive variant) Hereditary spastic paraplegia (many variants, some subtypes with Endocrine abnormalities distal amyotrophy) Allgrove syndrome Progressive spinal muscular atrophy (some subtypes not related Diabetic ÔamyotrophyÕ Insulinoma causing neuropathy Spinobulbar muscular atrophy with/without dynactin or Hyperthyroidism with myopathy Hypothyroidism with myopathy Spinal muscular atrophy I–IV Brown–Vialetto–van Laere syndrome (early-onset bulbar and Hyperparathyroidism (secondary due to vitamin D deﬁciency) spinal ALS with sensorineural deafness) Hypokalemia (ConnÕs syndrome) Fazio–Londe syndrome (infantile progressive bulbar palsy) Harper–Young syndrome (laryngeal and distal spinal muscular Lead (?), mercury (?), cadmium, aluminium, arsenic, thallium, manganese, organic pesticides; neurolathyrism, konzo Monomelic sporadic spinal muscular atrophy (benign focal amyotrophy, including Hirayama syndrome) Acute poliomyelitis Polyneuropathies with dominating motor symptoms (like hereditary Post-poliomyelitis progressive muscular atrophy syndrome motor and sensory neuropathy type 2, hereditary motor HIV-1 (with vacuolar myelopathy) neuropathy type 5) HTLV-1-associated myelopathy (tropical spastic paraplegia) Familial amyloid polyneuropathy Benign fasciculations Syphilitic hypertrophic pachymeningitis Spinal encephalitis lethargica, varicella-zosterTrichinosis ALS, amyotrophic lateral sclerosis; MND, motor neuron disease; PSP, Brucellosis, cat-scratch disease Progressive supranuclear palsy.
Cachectic myopathy 50% of the cases [16–19] (class IV). An evolution of Carcinoid myopathy atypical symptoms and a lack of progression of typical symptoms are the most important Ôred ﬂagsÕ suggesting Inclusion body myositisInﬂammatory myopathies an alternative diagnosis . The diagnosis should be Nemaline myopathy regularly reviewed [18,19]. The revised El Escorial cri- teria [20, summarized in Table 4] are excessively restrictive and are not designed for use in routine clin- Neoplastic syndromes ical practice . The new Awaji electrodiagnostic Chronic lymphocytic leukaemiaIntramedullary glioma algorithm  added to the El Escorial criteria Lymphoproliferative disorders with paraproteinemia and/or improves diagnostic sensitivity with no loss in speciﬁc- oligoclonal bands in the cerebrospinal ﬂuid ity  and improves early diagnosis as shown in sev- Pancoast tumour syndrome eral class IV studies [24–27]. The clinician must decide, Paraneoplastic encephalomyelitis with anterior horn cell on the balance of probability, whether or not the patient has ALS, even in the absence of unequivocal Ó 2011 The Author(s)European Journal of Neurology Ó 2011 EFNS European Journal of Neurology P. M. Andersen et al.
Table 4 The Revised El Escorial research diagnostic criteria for ALS Table 5 How should a physician tell patients that they have ALS? with the Awaji electrodiagnostic algorithm included – a summary(Modiﬁed from  and ) Clinically deﬁnite ALS Quiet, comfortable and private UMN and LMN clinical signs or electrophysiological evidence In person, face-to-face Convenient time (at least 45–60 min) Clinically deﬁnite ALS – laboratory supported Enough time to ensure there is no rushing or UMN and/or LMN clinical signs in one region and the patient is a carrier of a pathogenic SOD1-gene mutation Make eye contact and sit close to the patient Clinically probable ALS Know the patient before the meeting, including the UMN and LMN clinical or electrophysiological evidence by LMN family, emotional and social situation, case history, and UMN signs in two regions with some UMN signs rostral to the and all relevant test results. Have all the facts at Clinically possible ALS Have the patientÕs support network present UMN and LMN clinical or electrophysiological signs in one region (relatives), it is often an advantage that the patients network ÔoutnumberÕ the hospital staff present at UMN signs in at least two regions, or the meeting. Have a clinical nurse specialist or UMN and LMN signs in two regions with no UMN signs rostral to social counsellor available.
LMN signs. Neuroimaging and laboratory studies (Table 2) have Find out what the patient already knows about the excluded other diagnoses.
Ascertain how much the patient wants to know ALS, amyotrophic lateral sclerosis; EMG, electromyography; LMN, about ALS and tailor your information accordingly lower motor neuron; UMN, upper motor neuron.
Give a warning comment that bad news is coming.
The whole truth may need to come by instalmentsUse the correct ALS-term, not Ôwear and tear of upper and lower motor neuron signs . Experience the motor nervesÕ suggests that pursuing an early diagnosis of ALS out- Explain the anatomy of the disease (make a simple weighs the potential increase in risk of misdiagnosis If the patient indicates that they want to know the course of the disease, be honest about the likelyprogression and prognosis, but give a broad time frame and recognise the limitations of any 1. The diagnosis should be pursued as early as possible.
Patients in whom ALS is suspected should be referred Say that there is currently no cure and symptoms with high priority to an experienced neurologist tend to steadily worsen Mention that prognosis is highly variable and that some patients survive for 5, 10 or more years 2. All suspected new cases should undergo prompt de- Acknowledge and explore the patientÕs reaction and tailed clinical and paraclinical examinations (see allow for emotional expression Tables 1 and 2) (GCPP).
Summarise the discussion verbally, in writing, and/ 3. In some cases, additional investigations may be or on an audiotape needed (see Table 2).
Allow time for questions Acknowledge that this is devastating news, but 4. Repetition of the investigations may be required if discuss reasons for hope such as research, drug initial tests are equivocal (GCPP).
trials and the variability of the disease 5. Review of the diagnosis is advisable if there is no Explain that the complications of ALS are treatable evidence of typical progression or the patient develops Reassure that every attempt will be made to atypical features (see Table 1) (GCPP).
maintain the patientÕs function and that thepatientÕs treatment decisions will be respected Reassure that the patient will continue to be cared for and will not be abandoned Breaking the news: communicating the diagnosis Inform about patient support groups (offer contact Imparting a diagnosis of ALS requires skill. If not details and leaﬂets) performed appropriately, the eﬀect can be devastating, Inform about neuroprotective treatment (i.e.
riluzole) and ongoing research leaving the patient with a sense of abandonment and Discuss opportunities to participate in research destroying the patient–physician relationship  (class treatment protocols (if available) III). More than half of surveyed patients and caregivers Acknowledge a willingness to get a second opinion if state that they are dissatisﬁed by the manner in which the patient wishes the diagnosis has been communicated [29,30] (class IV).
Emotional manner: warmth, caring, empathy, Studies of other fatal illnesses  demonstrate advan- Be honest and sympathetic, but not sentimental tages in using speciﬁc techniques such as those outlined Give news at the personÕs pace; allow the patient to in Table 5 . Patients/caregivers are more satisﬁed if dictate what he or she is told Ó 2011 The Author(s) European Journal of Neurology Ó 2011 EFNS European Journal of Neurology EFNS Task Force on Management of ALS Table 5 (Continued) are likely to contribute to the increased survival of thoseattending multidisciplinary clinics [36,38,40,41]. Ter- tiary centres can also increase quality of life of patients Simple and careful word choice, yet direct; no with ALS (class III), perhaps related to a greater pro- euphemisms or medical jargon vision of appropriate aids and appliances [40,42,43].
Modiﬁed from .
Recommendations1. Multidisciplinary care should be available for people eﬀective communication strategies are used, and more aﬀected by ALS. Attendance at multidisciplinary clinics time is spent discussing the diagnosis [30,33] (class IV).
may extend survival, decrease medical complications Callous delivery of the diagnosis may aﬀect the fami- (level B) and improve quality of life (level C).
liesÕ/carersÕ psychological adjustment to bereavement 2. The following specialists should be part of or readily later  (class IV).
available to the multidisciplinary clinic team: neurolo-gist, respiratory physician, gastroenterologist, rehabili- 1. The diagnosis should be communicated by a con- occupational therapist, speech therapist, respiratory sultant with a good knowledge of the patient (GCPP).
therapist, specialized nurse, physical therapist, dietitian, 2. The physician should start the consultation by asking psychologist, dentist and palliative care physician what the patient already knows or suspects (GCPP).
3. The diagnosis should be given in person, ensuring enough time for discussion (suggest at least 45–60 min).
2–3 months, although they may require more frequent Provide printed materials about the disease, about review in the months following diagnosis or in the later support and advocacy organizations and informative stages of disease, and less frequent review if their dis- websites. A copy letter summarising the discussion can ease is progressing slowly. The patient support team be helpful for patients and carers (GCPP).
should maintain regular contact with the patient and 4. Assure patients that they will not be ÔabandonedÕ by relatives between visits (GCPP).
healthcare services and will be supported by a profes- 4. Ideally, the patient should be followed by the same sional ALS care team (where available), with regular neurologist liaising closely with the patientÕs primary follow-up visits to a neurologist. Make arrangements care physician (family general practitioner) (GCPP).
for a ﬁrst follow-up visit, ideally within 2–4 weeks 5. Eﬀective channels of communication and co-ordi- nation are essential between the hospital-based multi- 5. Avoid the following: withholding the diagnosis, disciplinary clinic team, the primary healthcare sector, providing insuﬃcient information, imposing unwanted the palliative care team and community services information, delivering information callously, taking away or not providing hope (GCPP).
ALS caregivers and burden of care Multidisciplinary care ALS causes progressive loss of independence and an Specialist multidisciplinary clinics (tertiary centres) can increased need for help with activities of everyday life.
provide optimized diagnostic and management services Carers progressively increase the time they devote to for patients with ALS [28,32,35,36]. Comparisons caring . The caregiversÕ burden relates to personal between clinic-based cohorts and population-based and social restrictions and to psychological and emo- cohorts of patients have conﬁrmed a referral bias: patients attending multidisciplinary clinics tend to be frequently search for information about ALS, and younger and to have had symptoms for longer than many actively participate in interactions between the those who do not [35–39] (Class II). An independent patient and physician, from the time of diagnosis survival beneﬁt has been identiﬁed in two studies (Class through to decision-making regarding advance direc- II) [36,38], more relevant in bulbar patients, whilst an- tives and end-of-life care. Certain ALS symptoms cause other study has shown no eﬀect . Patients attending particular strain in carers. If the patient loses eﬀective multidisciplinary clinics have fewer hospital admissions communication, carers can become intellectually and and shorter inpatient stays than those who attend emotionally isolated. The use of augmentative alterna- general clinics  (Class II). The increased use of tive communication devices can help to restore com- riluzole and non-invasive ventilation, attention to munication. Several studies have shown that the nutrition and earlier referral to palliative care services provision of mechanical ventilation for patients causes Ó 2011 The Author(s)European Journal of Neurology Ó 2011 EFNS European Journal of Neurology P. M. Andersen et al.
particular strain on caregivers, reducing their quality of studies did not include patients with early disease. La- life and raising their responsibilities related to manag- ter, retrospective Phase IV studies from ﬁve clinical ing the ventilator and providing for the increasing databases indicate that the overall gain in survival (i.e.
caring costs (Class IV) [47–49]. Sexuality may be a over the whole extent of the disease course) may extend problematic issue for many ALS patient–caregiver from 6 (Class III) , 10 (Class IV) , 12 (Class IV) couples. Reported problems include decreased libido, , 14 (Class IV)  or 21 (Class IV)  months, passivity of the partner and the carerÕs own passivity.
although these estimates are almost certainly subject to The most frequent reasons cited were the physical statistical biases. The drug is safe, with few serious side weakness and the body image changes because of ALS eﬀects. Fatigue was a side eﬀect in 26% of patients (Class IV) .
taking riluzole compared with 13% receiving placebo Half of patients with ALS in a cohort from the UK (number needed to harm = 8) . Although patients and Germany died at home . The anticipation of with progressive muscular atrophy or primary lateral patientsÕ imminent deaths may increase caregiver dis- sclerosis were not included in the riluzole trials, path- tress and anxiety. However, Neudert et al. report that ological and genetic studies show that some patients most patients with ALS die peacefully and no patient with progressive muscular atrophy and primary lateral Ôchokes to deathÕ if good palliative care measures are in sclerosis fall within the ALS syndrome, so may beneﬁt place (Class IV) .
from the drug [16,65] (Class IV). Riluzole may have Some caregivers go through a grieving process starting little eﬀect in late-stage ALS, and it is not clear whether from the time that diagnosis is given [52,53]. Anticipa- and when treatment should be terminated. A large tion of future loss is as important as the loss itself in number of other drugs have been tested in ALS, leading to psychological diﬃculties. Caregivers risk unfortunately with negative results (Table 6).
feelings of burn out, repercussions from forced changesin living arrangements and ﬁnancial hardships [53,54].
Recommendations1. Patients with ALS should be oﬀered treatment with riluzole 50 mg twice daily (level A).
1. Caregivers should be acknowledged in their double 2. Treatment should be initiated as early as possible role in the disease process: they are the most important after diagnosis (GCPP). Realistic expectations for resource for the patient, yet they are aﬀected them- treatment eﬀects and potential side eﬀects should be selves, and their own needs as carers need to be discussed with the patient and caregivers (GCPP).
3. Patients with progressive muscular atrophy, primary 2. Ideally, caregivers should be involved from the time lateral sclerosis or hereditary spastic paraplegia should of diagnosis, whilst preserving patientsÕ autonomy as a rule not be treated with riluzole (GCPP).
4. Irrespective of familial disposition, all patients with a 3. CarersÕ own health needs should be considered.
symptomatic progressive MND and carrying a SOD1 Physical, psychological and spiritual support should be gene mutation should be oﬀered treatment with riluzole provided when needed (GCPP).
4. Maintaining communication between patients and 5. Currently, there is insuﬃcient evidence to recom- caregivers is important (GCPP).
mend treatment with vitamins, testosterone, antioxi- 5. The likelihood of a peaceful death process should be dants such as co-enzyme Q-10 and gingko biloba, communicated to patients and their caregivers/relatives interferons, Copaxone, KDI tripeptide, neurotrophic 6. Bereavement counselling and support should be factors (including BDNF, IGF-1 and mecasermin oﬀered to all caregivers (GCPP).
rinfabate), ceftriaxone, creatine, gabapentin, minocy-cline, stem cells or lithium (GCPP).
Symptomatic treatment To date, riluzole is the only drug that has been shown toslow the course of ALS in four Class I studies [55–58]; a Symptomatic treatment aims to improve the quality of Cochrane review has also been published . Oral life of patients and caregivers. Symptoms should be administration of 100 mg riluzole daily improved the treated as they become prominent and incapacitating.
1-year survival by 15% and prolonged survival by3 months after 18 monthsÕ treatment. There was a clear dose eﬀect. Eleven people needed to be treated Sialorrhoea (drooling or excessive salivation) is com- with riluzole to delay one death for 12 months. These mon and may be socially disabling. Amitriptyline is Ó 2011 The Author(s) European Journal of Neurology Ó 2011 EFNS European Journal of Neurology EFNS Task Force on Management of ALS Table 6 (Continued) Table 6 Summary of the most important controlled therapeuticstudies in amyotrophic lateral sclerosis Intracerebroventricular delivery of VEGF IGF-1, Insulin-like growth factor.
Branched-chain amino acids* *No therapeutic beneﬁt was observed.
often used, but there are no formal studies proving its Ciliary neurotrophic factor* eﬃcacy . Oral doses of 10 mg three times a day are often suﬃcient. Atropine drops, 0.5% or 1%, administered three or four times a day sublingually have the advantage of a short duration of action – valuable in patients who suﬀer from sialorrhoea Glial-derived neurotrophic factor* alternating with an uncomfortably dry mouth. Gly- copyrrolate (in nebulized or i.v. form) has been shown to be eﬀective in patients with ParkinsonÕs disease  (Class I), but there are no studies in ALS. Transder- mal hyoscine (scopolamine), 1.5 mg every third day, Lymphoid irradiation* reduces salivary ﬂow (Class IV) [68,69]. Care is needed in elderly patients, because of the frequent side eﬀects of confusion or loss of bladder control. Studies with botulinum toxin (type A) (Class IV) [70–72] and a single randomized trial with botulinum toxin type B (Class I)  injected into the salivary glands reduced saliva in patients with refractory sialorrhoea. The injections were well tolerated. Caution is needed in patients with signiﬁcant bulbar palsy as increased dysphagia may occur, with serious consequences .
Another option is external irradiation of the salivary glands, with four studies showing satisfactory results Verapamil*Vitamin E* (Class IV) [75–78]. Surgical interventions may lead to problematic eﬀects such as increased secretion of thick Ongoing Phase II/III trials (2009–2011) Cistanche total glycosidesCombination therapy (celecoxib, creatine, minocycline) Treat sialorrhoea in ALS with amitriptyline, oral or transdermal hyoscine, or sublingual atropine drops Granulocyte colony-stimulating factor 1. In patients with refractory sialorrhoea, botulinum R(+) pramipexole (KNS-760704) toxin injections into the parotid and/or submandibular gland are eﬀective and generally well tolerated (level B for botulinum toxin type B, level C for type A toxin).
2. Irradiation of the salivary glands may be tried when pharmacological treatment fails (GCPP).
3. Surgical interventions are not recommended (GCPP).
SOD1 DNA antisense oligonucleotidesTauroursodeoxycholic acid Phase III trials being planned or considered Bronchial secretions Patients with bulbar or respiratory insuﬃciency com- monly report diﬃculties in eﬀectively clearing tenacious IGF-1 – viral delivery sputum, and mucus accumulation is a negative prognostic factor in patients with ALS treated with Ritonavir and hydroxyurea non-invasive ventilation . The mucosa of the nasalcavity, larynx, trachea, bronchial airways and lungs Ó 2011 The Author(s)European Journal of Neurology Ó 2011 EFNS European Journal of Neurology P. M. Andersen et al.
contribute a constant ﬂow of serous and mucoid ﬂuids.
3. A combination of dextrometorphan and quinidine Medication with mucolytics like guaifenesin or N-ace- has been shown to be eﬀective (level A).
tylcysteine, a beta-receptor antagonist (such as meto-prolol or propranolol)  (Class IV), and/or an anticholinergic bronchodilator like ipratropium and/or Cramps may be a troublesome symptom, particularly at theophylline, or even furosemide, may be of value, but night. A single randomized controlled trial with tetra- no controlled studies in ALS exist. Mechanical cough- hydrocannnabinol failed to show eﬃcacy in patients assisting devices (insuﬄator–exsuﬄator) via a face with ALS with moderate to severe cramps  (Class I).
mask have been eﬀective in patients with ALS in Levetiracetam was beneﬁcial in an open-label small uncontrolled trials [82,83] (Class IV).
pilot study  (Class IV). Quinine sulphate has beenbanned by the FDA because of safety concerns .
However, a recent Cochrane Review in non-ALS 1. A mucolytic including N-acetylcysteine, 200–400 mg cramps found quinine sulphate to be eﬀective with no three times daily, may be beneﬁcial (GCPP).
diﬀerence serious adverse events between the placebo 2. Beta-receptor antagonists and a nebulizer with saline and active drug . Treatments such as massage, and/or an anticholinergic bronchodilator and/or a physical exercise, hydrotherapy in heated pools, car- mucolytic and/or furosemide may be used in combi- bamazepine, diazepam, phenytoin and verapamil have nation. Mucolytics should only be used if suﬃcient been tried, but there are no controlled studies in ALS.
cough ﬂow is present (GCPP).
3. The patient and carer should be taught the technique of assisting expiratory movements using a manual-assisted 1. Levetiracetam may be tried. If unsuccessful or side cough (can also be performed by a physical therapist) eﬀects, quinine sulphate (200 mg twice daily) may be of beneﬁt (GCPP).
4. The use of a mechanical insuﬄator–exsuﬄator may 2. Physiotherapy, physical exercise and/or hydrother- be helpful, particularly in the setting of an acute apy may be helpful (GCPP).
respiratory infection (GCPP).
5. A portable home suction device and a room humidiﬁer may be of use (GCPP).
Physical therapy is the mainstay of treatment of spas-ticity in ALS and has been found eﬀective (Class III) Pseudobulbar emotional lability . Other interventions such as hydrotherapy, heat, Emotional lability occurs in at least 50% of patients cold, ultrasound, electrical stimulation, chemodener- with ALS irrespective of the presence or absence of vation and in rare cases surgery have been used, bulbar motor signs . Emotional lability does not although no controlled studies in ALS exist. In patients correlate with cognitive impairment . Prominent with ALS, intractable spasticity, and associated pain, pseudobulbar features such as pathological weeping, intrathecal baclofen was more eﬀective than oral med- laughing or yawning can be socially disabling and aﬀect ication and greatly improved patientsÕ quality of life patientsÕquality of life. The most commonly used agents (Class IV) [95,96]. Although not formally tested in are tricyclic antidepressants and selective serotonin ALS, in clinical practice, gabapentin (900–2400 mg reuptake inhibitors (SSRIs), which were eﬀective in daily), tizanidine (6–24 mg daily), memantine (10– small placebo-controlled studies or case series [86,87] 60 mg daily), dantrolene (25–100 mg daily), tetrazepam (Class IV). Two randomized controlled trials of a ﬁxed (100–200 mg daily) and diazepam (10–30 mg daily) dose combination of dextrometorphan and quinidine have been used. Botulinum toxin A has successfully have shown eﬃcacy in improving emotional lability and been used to treat trismus and stridor in single cases quality of life [88,89] (Class I). This medication has been approved by the US FDA.
1. Regular physical therapy can help relieve signiﬁcant 1. Inform the patient and relatives that emotional spasticity (GCPP).
lability is not a sign of an additional mood disorder but 2. Antispastic drugs such as baclofen and tizanidine is because of the eﬀects of ALS on the brain (GCPP).
may be tried (GCPP).
2. Troublesome emotional lability should be treated 3. If spasticity is severe despite oral medications, (GCPP). Antidepressants such as amitriptyline (in intrathecal baclofen may be helpful (GCPP).
particular in patients with drooling), ﬂuvoxamine and 4. Hydrotherapy with exercises in warm pools (32– citalopram are usually suﬃcient (level C).
34°C) and cryotherapy may be considered (GCPP).
Ó 2011 The Author(s) European Journal of Neurology Ó 2011 EFNS European Journal of Neurology EFNS Task Force on Management of ALS Depression and anxiety There are no studies regarding the management of DVT Depression and anxiety occur frequently in patients in patients with ALS.
with ALS and their caregivers . Anxiety is particu-larly prevalent during the diagnostic and terminal phases . No formal studies with antidepressants 1. DVT should be treated with anticoagulants (GCPP).
have been conducted in patients with ALS, but empir- 2. The optimum management of risk factors for venous ically tricyclic antidepressants (e.g. amitriptyline) and thrombosis should be pursued. Physiotherapy, limb SSRIs such as escitalopram may be eﬀective. Mirtaza- elevation and compression stockings are recommended pine may be better tolerated in the later stages than SSRIs or amitriptyline. The choice may be guided by 3. There is currently insuﬃcient evidence to recommend additional symptoms (e.g. sialorrhoea, insomnia, apa- prophylactic medical treatment with anticoagulants.
thy, appetite loss), which are diﬀerently aﬀected by thevarious antidepressants. There are no systematic studies Unproven therapies on anxiolytics in ALS. Some antidepressants, such asescitalopram, exert anxiolytic eﬀects, but additional Patients with ALS frequently use complementary and oral diazepam or sublingual lorazepam, may be neces- alternative medicines (CAM) suchs as vitamins, herbal supplements, homoeopathy and acupuncture .
Series of Class IV trials have tested interferon-alfa , human recombinant SOD1 , ciliary neurotrophic 1. Treat depression in ALS with an appropriate anti- factor , brain-derived neurotrophic factor  depressant, for example amitriptyline, an SSRI, or and similar drugs, all without evidence of clinical ben- mirtazapine. SSRI may be preferably in elderly or eﬁt. Insulin-like growth factor-1 has been injected cognitively impaired patients (GCPP).
intrathecally safely, with a modest clinical eﬀect 2. Treat anxiety with bupropion or benzodiazepines reported  (Class IV). In randomized, controlled such as diazepam tablets or suppositories, Temesta and open studies, liquorpheresis (ﬁltration of cerebro- tablets 0.5 mg two or three times daily, or sublingual spinal ﬂuid) has been performed in 11 patients with lorazepam (GCPP).
ALS, without clinical eﬀect [111,112] (Class IV). APhase 1 safety study of hyperbaric oxygen therapy Insomnia and fatigue reported some eﬃcacy on fatigue in four of ﬁve patients Insomnia is common in the ﬁnal months of life in with ALS , whilst a phase II study was reported as patients with ALS . There are likely to be several negative  (Class IV). Repetitive transcranial mag- causes, including depression, cramps, pain and respi- netic stimulation of the motor cortex had a beneﬁcial ratory distress, which if identiﬁed should be treated.
eﬀect in a pilot trial (Class IV)  but did not delay For insomnia in ALS, amitriptyline and zolpidem are functional deterioration in a double-blind placebo- the most commonly used medications . Fatigue is a controlled study in 20 patients  (Class III).
frequent and potentially debilitating symptom. It may Stem cell therapy is still in experimental development be of central and/or peripheral origin . One open- in ALS. The intravenous, intrathecal or intraparen- label study and one small Class I study with modaﬁnil chymal administration of haematopoietic stem cells revealed a signiﬁcant reduction of fatigue with a num- derived from peripheral blood or bone marrow has ber-needed-to-treat of 1.6 [101,102]. However, the long- been tested in small series of patients [117–122] (Class term eﬀects in ALS have not yet been studied.
IV). Even if these procedures are safe in the short term,the studies to date have not yielded suﬃciently robust data to allow translation to clinical practice .
1. Treat insomnia with amitriptyline, mirtazapine or Clinical eﬃcacy is unproven, and long-term safety still appropriate hypnotics (e.g. zolpidem) (GCPP).
needs to be demonstrated.
2. For debilitating fatigue, modaﬁnil may be considered A number of patients with ALS have, in a non-scientiﬁc setting, received intracerebral transplantation of olfac-tory ensheathing cells [124,125], resulting in serious side Venous thrombosis eﬀects in some  (Class IV).
Patients with ALS have an increased risk of deepvenous thrombosis (DVT), with an annual incidence rate of at least 2.7% [103,104]. The increased risk cor- 1. Before cellular therapies become a reality, a more relates with greater immobility and impaired respira- thorough preclinical evaluation and elucidation of tory function, but is independent of the patientÕs age.
several open questions is mandatory (GCPP).
Ó 2011 The Author(s)European Journal of Neurology Ó 2011 EFNS European Journal of Neurology P. M. Andersen et al.
2. No well-designed clinical trials testing cellular ther- 127] (Class IV). There is no speciﬁc therapy for patients apies have as yet been completed demonstrating safety with SOD1 gene mutations, but three clinical trials and clinical eﬃcacy supported by pathological evidence targeting SOD1 speciﬁcally are currently underway.
in a suﬃcient number of patients.
Presymptomatic (predictive) genetic testing is possible 3. Patients with ALS should be carefully informed but is a sensitive issue with emotional, ethical and legal about existing reliable data related to cell therapies. All implications that must be addressed before analysis current treatments with cell transplantation are purely should take place . Special consideration should be experimental, and there is no proven eﬀect on disease taken before presymptomatic testing is performed in outcome. If they decide to undergo transplantation, familial ALS families where the mutation is associated thorough examination before and after the stem cell with reduced disease penetrance or variable prognosis treatment should be performed and documented to (Class IV) [65,127,130].
improve the knowledge of beneﬁts and/or side eﬀects(GCPP).
4. Accurate and unbiased information related to cell 1. In all patients with suspected ALS, progressive therapies and other unproven/alternative therapies muscular atrophy, primary lateral sclerosis or fronto- needs to be delivered to the patient community (GCPP).
temporal dementia, a detailed medical history of the 5. All procedures involving the injection and trans- patient, siblings, parents and grandparents and their plantation of stem cells to a patient with ALS should be siblings should be obtained to potentially disclose a considered experimental and should be approved by a medical research ethical review board and performed in full accordance with the Declaration of Helsinki 2. Clinical DNA analysis for gene mutations should (WMA, 1964) (GCPP).
only be performed in cases with a known family historyof ALS, and in sporadic ALS cases with the charac-teristic phenotype of the recessive D90A mutation Genetic testing and counselling In diﬀerent populations, the frequency of familial ALS 3. Clinical DNA analysis for gene mutations should not is between 5 and 23% of all ALS cases [2,3,127]. Since be performed in cases with sporadic ALS with a typical 1993, mutations in ten genes – SOD1, VAPB, SETX, classical ALS phenotype (GCPP).
ALSIN, ANG, FUS, TARDBP, ATXN2, OPTN and 4. In familial or sporadic cases where the diagnosis is VCP – have been associated with ALS (http://alsod.
uncertain, SMN, androgen receptor or TARDBP, FUS, iop.kcl.ac.uk/als/). Mutations in the latter nine genes ANG or SOD1 DNA analysis may accelerate the appear to be rare, it is unclear whether all reported diagnostic process (GCPP).
mutations are pathogenic, and analysis of these genes is 5. Before blood is drawn for DNA analysis, the patient at present usually only performed in research settings. A should receive genetic counselling. Give the patient time few patients (often diagnosed as sporadic ALS) with for consideration. DNA analysis should be performed mutations in other genes have also been reported, but only with the patientÕs informed consent (GCPP).
causation remains to be proved. Since 1993, 164 muta- 6. Presymptomatic genetic testing should only be per- tions have been reported in the SOD1 gene (http:// formed in ﬁrst-degree adult blood relatives of patients alsod.iop.kcl.ac.uk/als/). The most frequent mutation is with a known gene mutation. Testing should only be the D90A, which in many European countries is inher- performed on a strictly voluntary basis as outlined ited as a recessive trait with a characteristic slowly (Table 7) and should follow accepted ethical principles progressing phenotype, although pedigrees with domi- nantly (heterozygous) inherited D90A-SOD1 and an 7. Results of DNA analysis performed on patients and aggressive phenotype have also been reported [65,128].
their relatives as part of a research project should not be Around 12–23% of patients diagnosed with familial used in clinical practice or disclosed to unaﬀected rela- ALS carry a SOD1 mutation . SOD1, FUS and tives. The research results should be kept in a separate ﬁle TARDBP mutations have been described in a small and not in the patientÕs standard medical chart (GCPP).
proportion of apparently sporadic patients with ALS,suggesting that some mutations have reduced disease Respiratory management in patients with ALS penetrance [http://alsod.iop.kcl.ac.uk/als/, 65,127–130].
A DNA SOD1 diagnostic test speeds up the diagnostic Respiratory complications are the main cause of death process and can be of help in diagnosing patients with in ALS (Fig. 1), primarily as a consequence of atypical features [65,127,130], as well as providing some diaphragmatic weakness combined with aspiration and infection . Erect forced vital capacity and vital Ó 2011 The Author(s) European Journal of Neurology Ó 2011 EFNS European Journal of Neurology EFNS Task Force on Management of ALS Table 7 Guidelines for presymptomatic genetic testing amyotrophic lateral sclerosis The test subject should belong to a family with a known SOD1, FUS or TARDBP gene mutation The test subject should be a ﬁrst-degree relative of an affected blood relative, or a second-degree relative of an affected case if the ﬁrst-degree relative is deceased The test subject should be 18 years or older The test subject should be mentally and physically healthy The test subject should not be under emotional stress (e.g. recently married or divorced, has become unemployed, pregnant, etc.) The test subject should participate as a volunteer without inﬂuence from a third party The test subject should receive a minimum of two genetic counselling sessions before the blood is drawn The test subject can request more than two genetic counselling sessions Genetic counselling should be given by professionals with a speciﬁc knowledge about amyotrophic lateral sclerosis and genetics After the blood sample has been drawn, the mutation analysis should be performed as quickly as possible to minimise the emotional discomfort of the procedure The test subject should be informed of the test result at a personal meeting with a genetic counsellor. The test result should never be given by letter or electronic communication It is advisable that the test subject be accompanied by a close friend at the genetic counselling sessions and when the test result is announced The test subject can at any time demand that the blood sample and test records be destroyed The test subject can at any time and without explanation withdraw from the test procedure and choose not to be informed of the test result Professional and community resources should be available to deal with the impact of the test result on the test subject and relatives The test result is private and should be kept in a separate ﬁle in the medical chart The test result is private, and no third party can request taking part in the result (unless regulated otherwise by national legislation) Respiratory symptoms Table 8 Symptoms and signs of respiratory insufﬁciency in amyo- and signs (table 8) trophic lateral sclerosis Discuss respiratory Dyspnoea on minor exertion treatment options with patient and family Use of auxilliary respiratory If severe bulbar Frequent nocturnal awakenings Paradoxical movement of the Excessive daytime sleepiness Decreased chest wall movement Difﬁculty clearing secretions Morning confusion, hallucinations Propose invasive Poor concentration and/or mechanical ventilation Modiﬁed from Leigh et al. .
nerve responses may predict hypoventilation in ALS Figure 1 Flowchart for the management of respiratory dysfunc- . Blood gas abnormalities are generally a late tion in amyotrophic lateral sclerosis (ALS)/motor neuron disease ﬁnding. Cough eﬀectiveness can be assessed by mea- (MND). NIPPV, non-invasive positive pressure.
suring peak cough ﬂow .
Non-invasive positive-pressure ventilation and, less capacity are the most widely used tests to evaluate frequently, invasive mechanical ventilation (IMV) are respiratory function and should be performed regularly, used to alleviate symptoms of respiratory insuﬃciency along with an assessment of symptoms suggestive of and prolong survival. There is no clear evidence respiratory insuﬃciency (Table 8). Sniﬀ nasal pressure regarding the timing and criteria for use of NIPPV and (SNP) may be more accurate in patients with weak lips, IMV in patients with ALS (Table 9). The use of but neither forced vital capacity nor SNP is a sensitive predictor of respiratory insuﬃciency in patients with reﬂecting economic and cultural diﬀerences [28,142].
severe bulbar involvement . Percutaneous noctur- Ideally, the patientÕs advance directives and a plan for nal oximetry is an easy tool to screen patients with and management of respiratory insuﬃciency should be can be useful to determine the need for non-invasive established before respiratory complications occur positive-pressure ventilation (NIPPV) . Phrenic Ó 2011 The Author(s)European Journal of Neurology Ó 2011 EFNS European Journal of Neurology P. M. Andersen et al.
Table 9 Proposed criteria for NIPPV [from references 28,135,138] Table 10 The advantages and drawbacks of invasive mechanicalventilation Symptoms/signs related to respiratory muscle weakness. At least oneof the following Increases survival time Prevents aspiration Ability to provide more effective ventilator pressures and better gas Disturbed sleep due to nocturnal desaturation/arousals Use of auxiliary respiratory muscles at rest Generates more bronchial secretions Paradoxical respiration Increases risk of infection Introduces risk of tracheo-oesophageal ﬁstula, tracheal stenosis or Excessive daytime sleepiness (ESS > 9) Abnormal respiratory function tests. At least one of the following Greatly increased costs Forced vital capacity <80% of predicted value Increased family and carer burden, including 24-h nursing Sniff nasal pressure <40 cmH2O PI max <60 mmH2O Ethical issues regarding discontinuation Signiﬁcant nocturnal desaturation on overnight oximetryMorning blood gas pCO2 > 45 mmHg ESS, Epworth Sleepiness Score; NIPPV, non-invasive positive- 1. Symptoms or signs of respiratory insuﬃciency(including symptoms of nocturnal hypoventilation) Non-invasive positive-pressure ventilation increases should be checked at each visit (GCPP).
survival and improves patientsÕ quality of life and is the 2. Forced vital capacity and vital capacity are the most preferred therapy to alleviate symptoms of respiratory available and practical tests for the regular monitoring insuﬃciency [47,49,137–142] (of which  is Class I).
of respiratory function (GCPP).
Treatment is usually initiated at night to alleviate 3. SNP may be used for monitoring, particularly in symptoms of nocturnal hypoventilation (Table 9).
bulbar patients with weak lips (GCPP).
NIPPV improves quality of life and prolongs survival in 4. Percutaneous nocturnal oximetry is recommended as a screening test and for monitoring respiratory function although this has not been conﬁrmed in patients with bulbar onset disease [140,142]. Patients with bulbar palsy 5. Symptoms or signs of respiratory insuﬃciency should are less compliant with NIPPV, due in part to increased prompt discussions with the patient and caregivers secretions . The use of diaphragmatic pacing or about treatment options and the terminal phase. Early respiratory exercises in ALS is not established [143,144].
discussions are needed to allow advance planning and Invasive mechanical ventilation can prolong survival directives (GCPP).
in ALS, in some cases for many years. However, no 6. NIPPV should be considered in preference to IMV in documented improvement in quality of life has been patients with symptoms or signs of respiratory insuﬃ- reported, and there is a risk that some patients will ciency (GCPP).
develop a Ôlocked-inÕ state. The availability and cultural 7. NIPPV can prolong survival for many months (level acceptability of IMV in patients with ALS varies A) and may improve the patientÕs quality of life greatly between diﬀerent countries and cultures. It is costly and has signiﬁcant emotional and social impacts 8. Active management of secretions and provision of on patients and caregivers (Table 10) [33,48,145,146].
cough-assist devices can increase the eﬀectiveness of Parenteral morphine, a benzodiazepine and an assisted ventilation in ALS (GCPP).
antiemetic are used when the patient decides that ven- 9. IMV has a major impact upon caregivers and tilatory support should be withdrawn . There is should be initiated only after informed discussion Class I evidence for the use of opioids and/or oxygen to treat dyspnoea in patients with terminal cancer or 10. Unplanned (emergency) IMV should be avoided chronic obstructive pulmonary disease [reviewed in through an early discussion of end-of-life issues, co- 147,148], but no controlled studies in ALS exist.
ordination with palliative care teams and appropriate Improving the clearance of bronchial secretions is advance directives (GCPP).
important in patients with ALS to promote quality of 11. Oxygen therapy alone should be avoided as it may life, improve NIV tolerance and decrease the risk of exacerbate carbon dioxide retention and oral dryness.
infection . Cough-assisting devices and chest wall Use oxygen only if symptomatic hypoxia is present oscillation may be of value [149,150].
Ó 2011 The Author(s) European Journal of Neurology Ó 2011 EFNS European Journal of Neurology EFNS Task Force on Management of ALS 12. The medical treatment of intermittent dyspnoea factory and better tolerated than PEG [158–161], but PRG is not widely available. NGT insertion is a minor a for short dyspnoeic bouts: relieve anxiety and give procedure that can be performed on all patients, but it lorazepam 0.5–2.5 mg sublingually; can have drawbacks such as increasing oropharyngeal b for longer phases of dyspnoea (>30 min): give mor- secretions or causing nasopharyngeal discomfort or phine 2.5 mg orally or s.c. (GCPP) even ulceration [162,163].
Recent studies suggest that home parenteral nutrition 13. For the medical treatment of chronic dyspnoea, is possible as an alternative to enteral feeding in patients start with morphine 2.5 mg orally four to six times with advanced ALS and poor respiratory function daily. For severe dyspnoea, give morphine s.c. or as [163,164] (Class IV).
an i.v. infusion. Start with 0.5 mg/h and titrate. Ifneeded, add midazolam (2.5–5 mg) or diazepam for nocturnal symptom control and to relieve anxiety 1. Bulbar dysfunction and nutritional status, including body weight, should be checked at each visit. Diﬃcultydrinking tap water is frequently the ﬁrst sign of signif-icant dysphagia (GCPP).
Enteral nutrition in patients with ALS 2. Patients should be referred to a dietitian as soon as Weight loss at time of diagnosis is an independent dysphagia appears. A speech and language therapist prognostic factor of survival in ALS . Data indi- can give valuable advice on swallowing techniques cate that patients with ALS have an increased resting energy expenditure . The initial management of 3. The timing of PEG/PRG is based on an individual dysphagia is based on the following: dietary counsel- approach taking into account bulbar symptoms, mal- ling, modiﬁcation of food and ﬂuid consistency nutrition (weight loss of over 10%), respiratory func- (blending food, adding thickeners to liquids), prescrip- tion and the patientÕs general condition. Early insertion tion of high-protein and high-caloric supplements, of a feeding tube is recommended (GCPP).
education of the patient and carers in feeding and 4. When PEG is indicated, patient and carers should be swallowing techniques such as supraglottic swallowing informed: (i) of the beneﬁts and risks of the procedure; and postural changes [153,154] and ﬂexing the neck (ii) that it is possible to continue to take food orally as forward on swallowing to protect the airway (Ôchin-tuck long as it is possible; and (iii) that deferring PEG to a manoeuvreÕ). Some patients with diﬃculty swallowing late disease stage may increase the risk of the procedure tap water can more easily drink carbonated ﬂuids and/ or ice-cold liquids. When tube feeding is needed, three 5. PRG is a suitable alternative to PEG. This procedure procedures obviate the need for major surgery and can be used as the procedure of choice or when PEG is general anaesthesia: percutaneous endoscopic gastros- deemed hazardous (GCPP).
tomy (PEG), percutaneous radiologic gastrostomy 6. Tubes with relatively large diameter (e.g. 18–22 (PRG, or radiologically inserted gastrostomy) and Charrie re) are recommended for both PEG and PRG to nasogastric tube (NGT) feeding.
prevent tube obstruction (GCPP).
Percutaneous endoscopic gastrostomy is the standard 7. Prophylactic medication with antibiotics on the day procedure for enteral nutrition in ALS and is widely of the operation may reduce the risk of infection available [153,154]. PEG improves nutrition, but there is no convincing evidence that it prevents aspiration or 8. NGT feeding may be used in the short-term and improves quality of life or survival  (Class III). The when PEG or PRG is not suitable (GCPP).
procedure requires mild sedation and is therefore more 9. Home parenteral nutrition may be used in patients hazardous in patients with respiratory impairment and/ with advanced ALS (GCPP).
or at an advanced stage of the disease [153,154]. Non-invasive ventilation during the PEG procedure may befeasible in patients with respiratory impairment (Class IV) . The timing of PEG is mainly based on Amyotrophic lateral sclerosis is associated with a symptoms, nutritional status and respiratory function frontotemporal syndrome in a signiﬁcant proportion of . To minimize risks, PEG should be performed cases, and these patients have a shorter survival [165– before vital capacity falls below 50% of predicted [154– 167] (Class IV). Approximately 5–15% of patients with 156] (Class IV). PRG is a newer alternative to PEG and ALS meet the diagnostic criteria for frontotemporal has the major advantage that it does not require patient dementia, typically frontal variant with executive dys- sedation for insertion [155–158]. PRG may be as satis- function and behaviour change [168,169] (Class III) Ó 2011 The Author(s)European Journal of Neurology Ó 2011 EFNS European Journal of Neurology P. M. Andersen et al.
although progressive aphasias have been described. A evidenced by reduced verbal output, reduced spelling further third of patients show mild cognitive (ALSci) ability, increased word-ﬁnding diﬃculties and impaired and/or behavioural (ALSbi) impairment [168,169].
auditory comprehension of speciﬁc classes of language ALSci is associated with early deﬁcits in verbal (letter) (e.g. verbs more than nouns) and more complex lan- ﬂuency and a mild dysexecutive syndrome , (Class guage constructs [179–181]. Deﬁcits may be subtle and III). Language changes are sometimes reported as are only identiﬁable with formal neuropsychological testing symptoms of memory impairment, but these are more [170,182]. Language impairment can reduce the quality likely due to an encoding rather than a retention deﬁcit of life of both patients and carers and can make clinical . ALSbi shows behaviour change that partially management diﬃcult (Class IV) . Formal neuro- meets criteria for frontotemporal dementia, with apathy psychological evaluation and support may be required most commonly reported [171,172] (Class IV). Impair- in patients with concomitant evolving language deﬁcits ment in emotional and social cognition has also been (see previous section). The overall goal should be to described [173,174] (Class III). Cerebral atrophy on optimize the eﬀectiveness of communication, concen- magnetic resonance imaging or ocular ﬁxation insta- trating on meaningful interpersonal communication bilities may be biomarkers of behavioural and cognitive with the primary carer and family. This should include abnormalities [175,176] (Class III).
strategies for eﬀective conversation and the introduc- A number of cognitive screening batteries have been tion of alternative communication devices where developed [177,178] (Class III),  (Class IV). Verbal (letter) ﬂuency deﬁcits are a sensitive measure of cog- Augmentative and alternative communication sys- nitive dysfunction if testing is appropriately modiﬁed tems can substantially improve the quality of life for for physical deﬁcits and results standardized to educa- both patients and carers. Prosthetic treatments (palatal tional attainment and premorbid IQ  (Class III).
lift and/or a palatal augmentation prosthesis) can be Carers may be unaware of mild impairment as useful in the reduction of hypernasality and improve- increasing physical disability results in a loss of ment of articulation, but no formal comparative studies autonomy and a greater reliance on others for daily in ALS exist. For those requiring full mechanical ven- tasks. Executive dysfunction may manifest as diﬃculties tilation, eye-pointing, eye-gaze or head-tracking aug- in managing aﬀairs/ﬁnances, planning for the future, mentative high-tech communication devices may be making decisions and learning new tasks, including the use of equipment associated with symptomatic treat-ment for ALS (e.g. gastrostomy, NIV).
Recommendations1. Regular assessment (i.e. every 3–6 months) of speech and language function by a trained speech and language 1. A frontotemporal syndrome occurs in up to half of therapist is recommended (GCPP).
patients with ALS (level B) and is associated with a 2. Those with evidence of early language deﬁcits should poorer prognosis. Symptoms of cognitive dysfunction undergo full neuropsychological testing (GCPP).
may appear before or after the onset of motor symptoms.
3. The use of appropriate communication support sys- 2. The Mini-Mental State Examination is an insensitive tems (ranging from pointing boards with ﬁgures or test for ALSci and ALSbi.
words, to computerized speech synthesizers) should be 3. Rapid screening tools that include tests of verbal individualized and appropriate training and support ﬂuency can identify patients in whom more detailed provided as required (GCPP).
neuropsychological evaluation is mandated (level C).
4. In all patients with frontal dysexecutive syndromes, Palliative and end-of-life care care needs to be taken to ensure informed consentduring decision-making; capacity issues may need to be A palliative care approach should be incorporated into considered (GCPP).
the care plan for patients and carers from the time of 5. Carers/healthcare professionals should be informed diagnosis . The aim of palliative care is to maxi- of the symptoms of dysexecutive syndrome and trained mize the quality of life of patients and families by in their management (GCPP).
relieving symptoms, providing emotional, psychologicaland spiritual support as needed, removing obstacles to apeaceful death and supporting the family in bereave- Communication in patients with ALS ment . Early referral to a specialist palliative care The majority of clinically apparent communication team is appropriate. Palliative care based in the com- diﬃculties in ALS result from dysarthria. However, munity or through hospice contacts (e.g. home care subtle changes in language function may also occur, as teams) can proceed in partnership with clinic-based Ó 2011 The Author(s) European Journal of Neurology Ó 2011 EFNS European Journal of Neurology EFNS Task Force on Management of ALS neurological multidisciplinary care. A small proportion Research recommendations of patients with ALS express interest in assisted suicide 1. Further studies of biomarkers (imaging, blood and  and may choose euthanasia where it is legalized cerebrospinal ﬂuid proteomics and metabolomics, neu- . Other aspects of terminal care have been covered rophysiological markers) to aid earlier speciﬁc ALS in previous sections.
diagnosis and to monitor possible eﬀects in clinical trials.
2. Further studies of the impact of specialist MND clinics on clinical outcomes, quality of life and carer 1. Whenever possible, oﬀer input from a palliative care team early in the course of the disease.
3. Further studies to optimize the symptomatic treat- 2. Initiate discussions on end-of-life decisions when the ment of muscle cramps, drooling and bronchial secre- patient asks or provides an opportunity for discussion tions in patients with ALS.
on the provision of end-of-life information and/or 4. Better criteria for deﬁning the use of PEG, PRG, NIV and IMV.
3. Discuss the options for respiratory support and end- 5. Further studies to evaluate the eﬀects of PEG/PRG, of-life issues if the patient has dyspnoea, other symp- cough-assisting devices and ventilation support on toms of hypoventilation (see Table 8) or a forced vital quality of life and survival.
capacity below 50%.
6. Further studies to evaluate language dysfunction and 4. Inform the patient of the legal situation regarding its treatment in ALS.
advance directives and the naming of a healthcare 7. Systematic studies to assess cognitive impairment and proxy. Oﬀer assistance in formulating an advance the frequency of frontal lobe dysfunction in ALS and to directive (GCPP).
standardize clinical, neuropsychological and neurora- 5. Re-discuss the patientÕs preferences for life-sustaining diological methods in this ﬁeld. Future ALS diagnostic treatments every 6 months (GCPP).
criteria should include parameters regarding cognitive 6. Initiate early referral to hospice or homecare teams dysfunction and dementia.
well in advance of the terminal phase of ALS (GCPP).
8. Studies of the medico-economical impact of more 7. Be aware of the importance of spiritual issues for the expensive procedures (NIV, IMV, cough-assisting quality of life and treatment choices. Establish a liaison devices, advanced communication equipment).
with local pastoral care workers to be able to address 9. Further studies to harmonize the patient databases of the needs of the patient and relatives (GCPP).
8. For the symptomatic treatment of dyspnoea and/or 10. Further studies on the psychosocial and spiritual intractable pain, use opioids alone or in combination determinants of quality of life in patients and their with benzodiazepines if anxiety is present. Titrating the family caregivers are needed, as well as studies on the dosages against the clinical symptoms will rarely if ever prevalence of, and determinants for, wishes for a has- result in life-threatening respiratory depression (GCPP).
9. Terminal restlessness and confusion because ofhypercapnia can be treated with neuroleptics (e.g.
Conflicts of interest chlorpromazine 12.5 mg every 4–12 h p.o., i.v., or p.r.)(GCPP).
Dr. Andersen has served as a consultant for Avanir 10. Use oxygen only if symptomatic hypoxia is present Pharmaceuticals. The other authors report no conﬂicts of interest.
Future developments Being a syndrome with low incidence and short sur-vival, most recommendations are GCPPs based on the The present guidelines were prepared without external consensus of experts in the ﬁeld of ALS. Further ran- ﬁnancial support.
domized and double-blind clinical trials are urgentlyneeded to improve the management of ALS.
Ó 2011 The Author(s)European Journal of Neurology Ó 2011 EFNS European Journal of Neurology EFNS Task Force on Management of ALS 20. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyo- 1. Andersen PM, Borasio GD, Dengler R, et al. EFNS trophic lateral sclerosis. Amyotroph Lateral Scler Other Task Force on Management of Amyotrophic Lateral Motor Neuron Disord 2000; 1: 293–299.
Sclerosis. Guidelines for diagnosing and clinical care of 21. Ross MA, Miller RG, Berchert L, et al. Towards earlier patients and relatives. An evidence-based review with diagnosis of ALS. Revised criteria. Neurology 1998; 50: Good Practice Points. Eur J Neurol 2005; 12: 921–938.
2. Forsgren L, Almay BG, Holmgren G, Wall S. Epide- 22. Carvalho M, Swash M. Awaji diagnostic algorithm miology of motor neuron disease in northern Sweden.
increases sensitivity of El Escorial criteria for ALS Acta Neurol Scand 1983; 68: 20–29.
diagnosis. Amyotroph Lateral Scler 2009; 10: 53–57.
3. Haverkamp LJ, Appel V, Appel SH. Natural history of 23. Douglass CP, Kandler RH, Shaw PJ, McDermott CJ.
amyotrophic lateral sclerosis in a database population.
An evaluation of neurophysiological criteria used in the Validation of a scoring system and a model for survival diagnosis of motor neurone disease. J Neurol Neurosurg prediction. Brain 1995; 118: 707–719.
Psychiatry 2010; 81: 646–649.
4. Scott KM, Abhinav K, Stanton BR, et al. Geographical 24. Okita T, Nodera H, Shibuta Y, et al. Can Awaji ALS clustering of amyotrophic lateral sclerosis in South-East criteria provide earlier diagnosis than the revised El England: a population study. Neuroepidemiology 2009; Escorial criteria? J Neurol Sci 2011; 302: 29–32.
25. Boekestein WA, Kleine BU, Hageman G, Schelhaas HJ, 5. Alonso A, Logroscino G, Jick SS, Herna´n MA. Incidence Zwarts MJ. Sensitivity and speciﬁcity of the ÔAwajiÕ and lifetime risk of motor neuron disease in the United electrodiagnostic criteria for amyotrophic lateral sclero- Kingdom: a population-based study. Eur J Neurol 2009; sis: retrospective comparison of the Awaji and revised El 10: 745–751.
Escorial criteria for ALS. Amyotroph Lateral Scler 2010; 6. Brainin M, Barnes M, Baron J-C, et al. Guidance for the 11: 497–501.
preparation of neurological management guidelines by 26. Chen A, Weimer L, Brannagan T, et al. Experience with EFNS scientiﬁc task forces – revised recommendations the Awaji Island modiﬁcations to the ALS diagnostic 2004. Eur J Neurol 2004; 11: 577–581.
criteria. Muscle Nerve 2010; 42: 831–832.
7. Li TM, Day SJ, Alberman E, Swash M. Differential 27. Schrooten M, Smetcoren C, Robberecht W, Van Damme diagnosis of motoneurone disease from other neurolog- P. Beneﬁt of the Awaji diagnostic algorithm for amyo- ical conditions. Lancet 1986; 2: 731–733.
trophic lateral sclerosis: a prospective study. Ann Neurol 8. Wilbourn AJ. Clinical neurophysiology in the diagnosis 2011; 70: 79–83.
of amyotrophic lateral sclerosis: the Lambert and the El 28. Leigh PN, Abrahams S, Al-Chalabi A, et al. The man- Escorial criteria. J Neurol Sci 1998; 160(Suppl. 1): S25– agement of motor neuron disease. J Neurol Neurosurg Psychiatry 2003; 70(Suppl. IV): iv32–iv47.
9. Meininger V. Getting the diagnosis right: beyond El 29. Borasio GD, Sloan R, Pongratz DE. Breaking the news Escorial. J Neurol 1999; 246(Suppl. 3): III10–III15.
in amyotrophic lateral sclerosis. J Neurol Sci 1998; 10. Rosen AD. Amyotrophic lateral sclerosis. Clinical fea- 160(Suppl. 1): S127–S133.
tures and prognosis. Arch Neurol 1978; 35: 638–642.
30. McCluskey L, Casarett D, Siderowf A. Breaking the 11. Chio A, Mora G, Calvo A, et al. Epidemiology of ALS news: a survey of ALS patients and their caregivers.
in Italy: a 10-year prospective population-based study.
Amyotroph Lateral Scler Other Motor Neuron Disord Neurology 2009; 72: 725–731.
2004; 5: 131–135.
12. Bromberg M. Accelerating the diagnosis of amyotrophic 31. Davies E, Hopkins A. Good practice in the management lateral sclerosis. Neurologist 1999; 5: 63–74.
of adults with malignant cerebral glioma: clinical 13. Aggarwal A, Nicholson G. Detection of preclinical guidelines. Working Group. Br J Neurosurg 1997; 11: motor neurone loss in SOD1 mutation carriers using motor unit number estimation. J Neurol Neurosurg 32. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice Psychiatry 2002; 73: 199–201.
parameter update: The care of the patient with amyo- 14. Brooks BR. Diagnostic dilemmas in amyotrophic lateral trophic lateral sclerosis: multidisciplinary care, symptom sclerosis. J Neurol Sci 1999; 165(Suppl 1): S1–S9.
management, and cognitive/behavioral impairment (an 15. Evangelista T, Carvalho M, Conceicao I, Pinto A, de evidence-based review): report of the Quality Standards Lurdes M, Luis ML. Motor neuropathies mimicking Subcommittee of the American Academy of Neurology.
amyotrophic lateral sclerosis/motor neuron disease.
Neurology 2009; 73: 1227–1233.
J Neurol Sci 1996; 139(Suppl.): 95–98.
33. Borasio GD, Shaw PJ, Hardiman O, et al. Standards 16. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, of palliative care for patients with amyotrophic lateral Hardiman O. Amyotrophic lateral sclerosis mimic syn- sclerosis: results of a European survey. Amyotroph dromes. Arch Neurol 2000; 57: 109–113.
Lateral Scler Other Motor Neuron Disord 2001; 2: 159– 17. Belsh JM, Schiffman PL. The amyotrophic lateral scle- rosis (ALS) patient perspective on misdiagnosis and its 34. Ackerman GM, Oliver D. Psychosocial support in an repercussions. J Neurol Sci 1996; 139(Suppl.): 110–116.
outpatient clinic. Palliat Med 1997; 11: 167–168.
18. Davenport RJ, Swingler RJ, Chancellor AM, Warlow 35. Howard RS, Orrell RW. Management of motor neurone CP. Avoiding false positive diagnoses of motor neuron disease. Postgrad Med J 2002; 78: 736–741.
disease: lessons from the Scottish Motor Neuron Disease 36. Chio A, Bottacchi E, Buffa C, Mutani R, Mora G.
Register. J Neurol Neurosurg Psychiatry 1996; 60: 147–151.
Positive effects of tertiary centres for amyotrophic lateral 19. Brooks BR. Earlier is better: the beneﬁts of early diag- sclerosis on outcome and use of hospital facilities.
nosis. Neurology 1999; 53(Suppl. 5): S53–S54.
J Neurol Neurosurg Psychiatry 2006; 77: 948–950.
Ó 2011 The Author(s) European Journal of Neurology Ó 2011 EFNS European Journal of Neurology P. M. Andersen et al.
37. Sorenson EJ, Mandrekar J, Crum B, Stevens JC. Effect 56. Lacomblez L, Bensimon G, Leigh PN, et al. Dose- of referral bias on assessing survival in ALS. Neurology ranging study of riluzole in amyotrophic lateral sclerosis.
2007; 68: 600–602.
Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
38. Traynor BJ, Alexander M, Corr B, et al. Effects of a Lancet 1996; 347: 1425–1431.
multidisciplinary ALS clinic on survival. J Neurol Neu- 57. Yanagisawa N, Tashiro K, Toghi T, et al. Efﬁcacy and rosurg Psychiatry 2003; 74: 1258–1261.
safety f riluzole in patients with amyotrophic lateral 39. Zoccolella S, Beghi E, Palagano G, et al. ALS multi- disciplinary clinic and survival. Results from a popula- Japan. Igakuno Ayumi 1997; 182: 851–866.
tion-based study in Southern Italy. J Neurol 2007; 254: 58. Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Trufﬁnet P, Meininger V. A study of riluzole in the 40. Mayadev AS, Weiss MD, Distad BJ, Krivickas LS, treatment of advanced stage or elderly patients with Carter GT. The amyotrophic lateral sclerosis center: a amyotrophic lateral sclerosis. J Neurol 2002; 249: 609– model of multidisciplinary management. Phys Med Rehabil Clin N Am 2008; 19: 619–631.
59. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole 41. Kareus SA, Kagebein S, Rudnicki SA. The importance for amyotrophic lateral sclerosis (ALS)/motor neuron of a respiratory therapist in the ALS clinic. Amyotroph disease (MND). Cochrane Database Syst Rev 2007; 2: Lateral Scler 2008; 9: 173–176.
42. Van den Berg JP, Kalmijn S, Lindeman E, et al. Multi- 60. Riviere M, Meininger V, Zeisser P, Munsat T. An disciplinary ALS care improves quality of life in patients analysis of extended survival in patients with ALS trea- with ALS. Neurology 2005; 65: 1264–1267.
ted with riluzole. Arch Neurol 1998; 55: 526–528.
43. Corr B, Frost E, Traynor BJ, Hardiman O. Service 61. Mitchell JD, O‘Brien MR, Joshi M. Audit of outcomes provision for patients with ALS/MND: a cost-effective in motor neuron disease (MND) patients treated with riluzole. Amyotroph Lateral Scler 2006; 7: 67–71.
160(Suppl. 1): S141–S145.
62. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman 44. Chio A, Gauthier A, Vignola A, et al. Caregiver time use O. An outcome study of riluzole in amyotrophic lateral in ALS. Neurology 2006; 67: 902–904.
sclerosis – a population-based study in Ireland, 1996– 45. Hecht MJ, Graesel E, Tigges S, et al. Burden of care in 2000. J Neurol 2003; 250: 473–479.
amyotrophic lateral sclerosis. Palliat Med 2003; 17: 327– 63. Brooks BR, Belden DS, Roelke K, et al. Survival in non- riluzole treated ALS patients is identical before and since 46. Gauthier A, Vignola A, Calvo A, et al. A longitudinal 1996: a clinic-based epidemiological study. Amyotroph study on quality of life and depression in ALS patient- Lateral Scler Other Motor Neuron Disord 2001; 2(Suppl.
caregiver couples. Neurology 2007; 68: 923–926.
2): 60–61. (Abstract #P15).
47. Gelinas DF, OÕConnor P, Miller RG. Quality of life for 64. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, ventilator-dependent ALS patients and their caregivers.
Al-Chalabi A. Prognostic modelling of therapeutic J Neurol Sci 1998; 160(Suppl. 1): S134–S136.
interventions in amyotrophic lateral sclerosis. Amyo- 48. Kaub-Wittemer troph Lateral Scler Other Motor Neuron Disord 2002; Laier-Groeneveld G, Borasio GD. Quality of life and psychosocial issues in ventilated patients with amyo- 65. Andersen PM, Sims KB, Xin WW, et al. Sixteen novel trophic lateral sclerosis and their caregivers. J Pain mutations in the gene encoding CuZn-superoxide Symptom Manage 2003; 26: 890–896.
dismutase in ALS. Amyotroph Lateral Scler Other Motor 49. Mustfa N, Walsh E, Bryant V, et al. The effect of non- Neuron Disord 2003; 2: 62–73.
invasive ventilation on ALS patients and their caregivers.
66. Forshew DA, Bromberg MB. A survey of cliniciansÕ Neurology 2006; 66: 1211–1217.
practice in the symptomatic treatment of ALS. Amyotroph 50. Wasner M, Bold U, Vollmer TC, Borasio GD. Sexuality Lateral Scler Other Motor Neuron Disord 2003; 4: 258– in patients with amyotrophic lateral sclerosis and their partners. J Neurol 2004; 251: 445–448.
67. Arbouw ME, Movig KL, Koopmann M, et al. Glyco- 51. Neudert C, Oliver D, Wasner M, Borasio GD. The pyrrolate for sialorrhea in Parkinson disease: a ran- course of the terminal phase in patients with amyo- domized, double-blind, crossover trial. Neurology 2010; trophic lateral sclerosis. J Neurol 2001; 248: 612–616.
52. Hebert RS, Lacomis D, Easter C, Frick V, Shear MK.
68. Talmi YP, Finkelstein Y, Zohar Y. Reduction of salivary Grief support for informal caregivers of patients with ﬂow in amyotrophic lateral sclerosis with scopoderm ALS: a national survey. Neurology 2005; 64: 137–138.
TTS. Head Neck 1989; 11: 565.
53. Paz-Rodriguez F, Andrade-Palos P, Llanos-Del Pilar 69. Talmi YP, Finkelstein Y, Zohar Y. Reduction of sali- AM. Emotional consequences of providing care to vary ﬂow with transdermal scopolamine: a four-year amyotrophic lateral sclerosis patients. Rev Neurol 2005; experience. Otolaryngol Head Neck Surg 1990; 103: 40: 459–464.
54. Martin J, Turnbull J. Lasting impact in families after 70. Giess R, Naumann M, Werner E, et al. Injections of death from ALS. Amyotroph Lateral Scler Other Motor botulinum toxin A into the salivary glands improve sia- Neuron Disord 2001; 2: 181–187.
lorrhoea in amyotrophic lateral sclerosis. J Neurol Neu- 55. Bensimon G, Lacomblez L, Meininger V, et al. A con- rosurg Psychiatry 2000; 69: 121–123.
trolled trial of riluzole in amyotrophic lateral sclerosis.
71. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G.
ALS/Riluzole Study Group. N Engl J Med 1994; 330: A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003; 61: 1279–1281.
Ó 2011 The Author(s)European Journal of Neurology Ó 2011 EFNS European Journal of Neurology EFNS Task Force on Management of ALS 72. Gilio F, Iacovelli E, Frasca V, et al. Botulinum toxin randomised, double-blind crossover trial. J Neurol Neu- type A for the treatment of sialorrhoea in amyotrophic rosurg Psychiatry 2010; 81: 1135–1140.
lateral sclerosis: a clinical and neurophysiological study.
91. Bedlack RS, Pastula DM, Hawes J, Heydt D. Open-label Amyotroph Lateral Scler 2010; 11: 359–363.
pilot trial of levetiracetam for cramps and spasticity in 73. Jackson CE, Gronseth G, Rosenfeld J, et al. Random- patients with motor neuron disease. Amyotroph Lateral ized double-blind study of botulinum toxin type B for Scler 2009; 10: 210–215.
sialorrhea in ALS patients. Muscle Nerve 2009; 39: 137– 92. Katzberg HD, Khan AH, So YT. Assessment: symp- tomatic treatment for muscle cramps (an evidence-based 74. Winterholler MG, Erbguth FJ, Wolf S, Kat S. Botu- review): report of the therapeutics and technology linum toxin for the treatment of sialorrhoea in ALS: assessment subcommittee of the American Academy of serious side effects of a transductal approach. J Neurol Neurology. Neurology 2010; 74: 691–696.
Neurosurg Psychiatry 2001; 70: 417–418.
93. El-Tawil S, Al Musa T, Valli H, et al. Quinine for muscle 75. Andersen PM, Gro¨nberg H, Funega˚rd U, Franzen L.
cramps. Cochrane Database Syst Rev 2010; 12: CB005044.
X-ray radiation of the parotid glands signiﬁcantly 94. Drory VW, Goltsman E, Renik JG, et al. The value of reduces drooling in patients with progressive bulbar muscle exercise in patients with amyotrophic lateral palsy. J Neurol Sci 2001; 191: 111–114.
sclerosis. J Neurol Sci 2001; 191: 133–137.
76. Harriman M, Morrison M, Hay J, et al. Use of radio- 95. Marquardt G, Seifert V. Use of intrathecal baclofen for therapy for control of sialorrhea in patients with amyo- treatment of spasticity in amyotrophic lateral sclerosis.
trophic lateral sclerosis. J Otolaryngol 2001; 30: 242–245.
J Neurol Neurosurg Psychiatry 2002; 72: 275–276.
77. Stalpers LJ, Moser EC. Results of radiotherapy for 96. McClelland S III, Bethoux FA, Boulis NM, et al.
drooling in amyotrophic lateral sclerosis. Neurology Intrathecal baclofen for spasticity-related pain in amyo- 2002; 58: 1308.
trophic lateral sclerosis: efﬁcacy and factors associated 78. Neppelberg E, Haugen DF, Thorsen L, Tysnes OB.
with pain relief. Muscle Nerve 2008; 37: 396–398.
Radiotherapy reduces sialorrhea in amyotrophic lateral 97. Winterholler MG, Heckmann JG, Hecht M, Erbguth FJ.
sclerosis. Eur J Neurol 2007; 14: 1373–1377.
Recurrent trismus and stridor in an ALS patient: suc- 79. Burton MJ. The surgical management of drooling. Dev cessful treatment with botulinum toxin. Neurology 2002; Med Child Neurol 1991; 33: 1110–1116.
80. Peysson S, Vandenberghe N, Phillit F, et al. Factors 98. Vignola A, Guzzo A, Calvo A, et al. Anxiety undermines predicting survival following noninvasive ventilation in quality of life in ALS patients and caregivers. Eur J amyotrophic lateral sclerosis. Eur Neurol 2008; 59: 164– Neurol 2008; 15: 1231–1236.
99. Wicks P, Abrahams S, Masi D, Hejda-Forde S, Leigh 81. Newall AR, Orser R, Hunt M. The control of oral PN, Goldstein LH. Prevalence of depression in a secretions in bulbar ALS/MND. J Neurol Sci 1996; 12-month consecutive sample of patients with ALS. Eur J Neurol 2007; 14: 993–1001.
82. Hanayama K, Ishikawa Y, Bach JR. Amyotrophic lat- 100. Lou JS. Fatigue in amyotrophic lateral sclerosis. Phys eral sclerosis: successful treatment of mucous plugging Med Rehabil Clin N Am 2008; 19: 533–543.
by mechanical insufﬂation-exsufﬂation. Am J Phys Med 101. Carter GT, Weiss MD, Lou JS, et al. Modaﬁnil to Rehabil 1997; 76: 338–339.
treat fatigue in amyotrophic lateral sclerosis: an open 83. Sancho J, Servera E, Diaz J, Marin J. Efﬁcacy of label pilot study. Am J Hosp Palliat Care 2005; 22: 55– mechanical insufﬂation-exsufﬂation in medically stable patients with amyotrophic lateral sclerosis. Chest 2004; 102. Rabkin JG, Gordon PH, McElhiney M, Rabkin R, 125: 1400–1405.
Chew S, Mitsumoto H. Modaﬁnil treatment of fatigue in 84. Gallagher JP. Pathologic laughter and crying in ALS: a patients with ALS: a placebo-controlled study. Muscle search for their origin. Acta Neurol Scand 1989; 80: 114– Nerve 2009; 39: 297–303.
103. Elman LB, Siderowf A, Houseman G, Kelley M, 85. Palmieri A, Abrahams S, Soraru G, et al. Emotional McCluskey LF. Venous thrombosis in an ALS popula- lability in MND: relationship to cognition and psycho- tion over four years. Amyotroph Lateral Scler Other pathology and impact on caregiver. J Neurol Sci 2009; Motor Neuron Disord 2005; 6: 246–249.
104. Qureshi MM, Cudkowicz ME, Zhang H, Raynor E.
86. Szczudlik A, Slowik A, Tomik B. The effect of amitrip- Increased incidence of deep venous thrombosis in ALS.
tyline on the pathological crying and other pseudobulbar Neurology 2007; 68: 76–77.
signs. Neurol Neurochir Pol 1995; 29: 663–674.
105. Wasner M, Klier H, Borasio GD. The use of alternative 87. Iannaccone S, Ferini-Strambi L. Pharmacologic treat- medicine by patients with amyotrophic lateral sclerosis.
ment of emotional lability. Clin Neuropharmacol 1996; J Neurol Sci 2001; 191: 151–154.
106. Mora JS, Munsat TL, Kao KP, et al. Intrathecal admin- 88. Brooks BR, Thisted RA, Appel SH, et al. Treatment of istration of natural human interferon alfa in amyotrophic pseudobulbar affect in ALS with dextromethorphan/ lateral sclerosis. Neurology 1986; 36: 1137–1140.
quinidine: a randomized trial. The AVP-923 ALS Study 107. Cudkowicz ME, EWarren L, Francis JW, et al. Intra- Group. Neurology 2004; 63: 1364–1370.
thecal administration of recombinant human superoxide 89. Pioro ET, Brooks BR, Cummings J, et al. Dextrometh- dismutase 1 in amyotrophic lateral sclerosis: a pre- orphan plus ultra low-dose quinidine reduces pseudo- liminary safety and pharmacokinetic study. Neurology bulbar affect. Ann Neurol 2010; 68: 693–702.
1997; 49: 213–222.
90. Weber M, Goldman B, Truniger S. Tetrahydrocannabi- 108. Aebischer P, Schluep M, De´glon N, et al. Intrathecal nol (THC) for cramps in amyotrophic lateral sclerosis: a delivery of CNTF using encapsulated genetically modi- Ó 2011 The Author(s) European Journal of Neurology Ó 2011 EFNS European Journal of Neurology P. M. Andersen et al.
ﬁed xenogeneic cells in amyotrophic lateral sclerosis sclerosis patients: a controlled pilot study. Clin Trans- patients. Nat Med 1996; 2: 696–699.
plant 2008; 22: 710–718.
109. Ochs G, Penn RD, York M, et al. A phase I/II trial of 125. Huang H, Chen L, Xi H, et al. Olfactory ensheathing recombinant methionyl human brain derived neuro- cells transplantation for central nervous system diseases trophic factor administered by intrathecal infusion to in 1,255 patients. Zhongguo Xiu Fu Chong Jian Wai Ke patients with amyotrophic lateral sclerosis. Amyotroph Za Zhi 2009; 23: 14–20.
Lateral Scler Other Motor Neuron Disord 2000; 1: 201–206.
126. Chen L, Huang H, Zhang J, et al. Short-term outcome of 110. Nagano I, Shiote M, Murakami T, et al. Beneﬁcial olfactory ensheathing cells transplantation for treatment effects of intrathecal IGF-1 administration in patients of amyotrophic lateral sclerosis. Zhongguo Xiu Fu Chong with amyotrophic lateral sclerosis. Neurol Res 2005; 27: Jian Wai Ke Za Zhi 2007; 21: 961–966.
127. Andersen PM, Abrahams S, Borasio GD, et al. Man- 111. Finsterer J, Mamoli B. Liquorpheresis (CSF ﬁltration) in agement of amyotrophic lateral sclerosis. In: Gilhus NE, familial amyotrophic lateral sclerosis. Spinal Cord 1999; Barnes MP, Brainin M eds. European Handbook of 37: 592–593.
Neurological Management, 2nd edn, vol 1, chapter 17.
112. Finsterer J, Mamoli B. Cerebrospinal ﬂuid ﬁltration in Chichester: Wiley-Blackwell, 2010: 283–310.
amyotrophic lateral sclerosis. Eur J Neurol 1999; 6: 597– 128. Andersen PM, Forsgren L, Binzer M, et al. Autosomal recessive adult-onset ALS associated with homozygosity 113. Steele J, Matos LA, Lopez EA, et al. A phase I safety for Asp90Ala CuZn-superoxide dismutase mutation. A study of hyperbaric oxygen therapy for amyotrophic clinical and genealogical study of 36 patients. Brain 1996; lateral sclerosis. Amyotroph Lateral Scler Other Motor 119: 1153–1172.
Neuron Disord 2004; 5: 250–254.
129. Jones CT, Swingler RJ, Simpson SA, Brock DJ. Super- 114. Steele J, Zutshi D, Bradley WG. Negative results of a oxide dismutase mutations in an unselected cohort of phase II study of hyperbaric oxygen therapy for amyo- Scottish amyotrophic lateral sclerosis patients. J Med trophic lateral sclerosis. Amyotroph Lateral Scler 2007; 8: Genet 1995; 32: 290–292.
130. Eisen A, Mezei MM, Stewart HG, Fabros M, Gibson G, 115. Zanette G, Forgione A, Manganotti P, Fiaschi A, Andersen PM. SOD1 gene mutations in ALS patients Tamburin S. The effect of repetitive transcranial mag- from British Columbia, Canada: clinical features, neu- netic stimulation on motor performance, fatigue and rophysiology and ethical issues in management. Amyo- quality of life in amyotrophic lateral sclerosis. J Neurol troph Lateral Scler 2008; 9: 108–119.
Sci 2008; 270: 18–22.
131. Fanos JH, Gronka S, Wuu J, et al. Impact of presymp- 116. Di Lazzaro V, Pilato F, Proﬁce P, et al. Motor cortex tomatic genetic testing for familial amyotrophic lateral stimulation for ALS: a double blind placebo-controlled sclerosis. Genet Med 2011; 13: 342–348.
study. Neurosci Lett 2009; 464: 18–21.
132. Gil J, Funalot B, Verschueren A. Causes of death 117. Janson CG, Ramesh TM, During MJ, Leone P, Heywood amongst French patients with amyotrophic lateral scle- J. Human intrathecal transplantation of peripheral blood rosis: a prospective study. Eur J Neurol 2008; 15: 1245– stem cells in amyotrophic lateral sclerosis. J Hematother Stem Cell Res 2001; 10: 913–915.
133. Lyall RA, Donaldson N, Polkey MI, Leigh PN, Mox- 118. Mazzini L, Mareschi K, Ferrero I, et al. Stem cell ham J. Respiratory muscle strength and ventilatory treatment in amyotrophic lateral sclerosis. J Neurol Sci failure in amyotrophic lateral sclerosis. Brain 2001; 124: 2008; 265: 78–83.
119. Appel SH, Engelhardt JI, Henkel JS, et al. Hematopoi- 134. Pinto A, de Carvalho M, Evangelista T, Lopes A, Sales- etic stem cell transplantation in patients with sporadic Luis L. Nocturnal pulse oximetry: a new approach to amyotrophic lateral sclerosis. Neurology 2008; 71: establish the appropriate time for non-invasive ventila- tion. Amyotroph Lateral Scler 2003; 4: 31–35.
120. Deda H, Inci MC, Ku¨rekc¸i AE, et al. Treatment of 135. Pinto S, Turkman A, Pinto A, Swash M, de Carvalho M.
amyotrophic lateral sclerosis patients by autologous Predicting respiratory insufﬁciency in amyotrophic bone marrow-derived hematopoietic stem cell trans- lateral sclerosis: the role of phrenic nerve studies. Clin plantation: a 1-year follow-up. Cytotherapy 2009; 11: 18– Neurophysiol 2009; 120: 941–946.
136. Sancho J, Servera E, Dias J, Marin J. Prediction of 121. Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, ineffective cough during a chest infection in patients with Caro E, Gutierrez-Jimenez E, Segura JJ. Stem-cell stable amyotrophic lateral sclerosis. Am J Respir Crit transplantation into the frontal motor cortex in amyo- Care Med 2007; 175: 1266–1271.
trophic lateral sclerosis patients. Cytotherapy 2009; 11: 137. Bourke SC, Gibson GJ. Non-invasive ventilation in ALS: current practice and future role. Amyotroph Lat- 122. Mazzini L, Ferrero I, Luparello V, et al. Mesenchymal eral Scler Other Motor Neuron Disord 2004; 5: 67–71.
stem cell transplantation in amyotrophic lateral scle- 138. Mendoza M, Gelinas DF, Moore DH, Miller RG. A rosis: a phase I clinical trial. Exp Neurol 2010; 223: comparison of maximal inspiratory and forced vital capacity as potential criteria for initiating non-invasive 123. Badayan I, Cudkowicz ME. Is it too soon for mesen- ventilation in ALS. Amyotroph Lateral Scler 2007; 8: chymal stem cell trials in people with ALS? Amyotroph Lateral Scler 2009; 10: 123–124.
139. Pinto A, Evangelista T, de Carvalho M, Alves MA, 124. Huang H, Chen L, Xi H, et al. Fetal olfactory Sales-Luis ML. Respiratory assistance with a non-inva- ensheathing cells transplantation in amyotrophic lateral sive ventilator (BiPAP) in MND/ALS patients: survival Ó 2011 The Author(s)European Journal of Neurology Ó 2011 EFNS European Journal of Neurology EFNS Task Force on Management of ALS rates in a controlled trial. J Neurol Sci 1995; 129(Suppl.): 155. Sancho J, Servera E, Chiner E, et al. Noninvasive respiratory muscle aids during PEG placement in ALS 140. Bourke SC, Tomlinson M, Williams TL, Bullock RE, patients with severe respiratory impairment. J Neurol Sci Shaw PJ, Gibson GJ. Effects of non-invasive ventilation 2010; 297: 55–59.
on survival and quality of life in patients with amyo- 156. Shaw AS, Ampong MA, Rio A, et al. Survival of trophic lateral sclerosis: a randomised controlled trial.
patients with ALS following institution of enteral feeding Lancet Neurol 2006; 5: 140–147.
is related to pre-procedure oximetry: a retrospective 141. Lo Cocco D, Marchese S, Pesco MC, La Bella V, Piccoli review of 98 patients in a single centre. Amyotroph Lat- F, Lo Cocco A. The amyotrophic lateral sclerosis func- eral Scler 2006; 7: 16–21.
tional rating scale predicts survival time in amyotrophic 157. Mathus-Vliegen LM, Louwerse LS, Merkus MP, Tytgat lateral sclerosis patients on invasive mechanical ventila- GN, Vianney de Jong JM. Percutaneous endoscopic tion. Chest 2007; 132: 64–69.
gastrostomy in patients with amyotrophic lateral scle- 142. Lechtzin N, Scott Y, Busse AM, Clawson LL, Kimball rosis and impaired pulmonary function. Gastrointest R, Wiener CM. Early use of non-invasive ventilation Endosc 1994; 40: 463–469.
prolongs survival in subjects with ALS. Amyotroph 158. Chio A, Galletti R, Finocchiaro C, et al. Percutaneous Lateral Scler 2007; 8: 185–188.
radiological gastrostomy: a safe and effective method of 143. Onders RP, Carlin AM, Elmo M, Sivashankaran S, nutritional tube placement in advanced ALS. J Neurol Katirii B, Schilz R. Amyotrophic lateral sclerosis: the Neurosurg Psychiatry 2004; 75: 645–647.
Midwestern surgical experience with diaphragm pacing 159. Shaw AS, Ampong MA, Rio A, McClure J, Leigh PN, stimulation system shows that general anesthesia can be Sidhu PS. Entristar skin-level gastrostomy tube: primary safely performed. Am J Surg 2009; 197: 386–390.
placement with radiologic guidance in patients with 144. Nardin R, O‘Donnell C, Loring SH, et al. Diaphragm amyotrophic lateral sclerosis. Radiology 2004; 233: 392– training in amyotrophic lateral sclerosis. J Clin Neu- romuscul Dis 2008; 10: 56–60.
160. Thornton FJ, Fotheringham T, Alexander M, Hardiman 145. Cazzolli PA, Oppenheimer EA. Home mechanical ven- O, McGrath FP, Lee MJ. Amyotrophic lateral sclerosis: tilation for amyotrophic lateral sclerosis: nasal compared enteral nutrition provision – endoscopic or radiologic to tracheostomy-intermittent positive pressure ventila- gastrostomy? Radiology 2002; 224: 713–717.
tion. J Neurol Sci 1996; 139(Suppl.): 123–128.
161. Blondet A, Lebigot J, Nicholas G, et al. Radiologic 146. Miller RG, Jackson CE, Kasarkis EJ, et al. Practise versus endoscopic placement of percutaneous gastro- Parameter update: the care of the patient with amyo- stomy in amyotrophic lateral sclerosis: multivariate trophic lateral sclerosis: drug, nutritional, and respira- analysis of tolerance, efﬁcacy and survival. J Vasc Interv tory therapies (an evidence-based review). Neurology Radiol 2010; 21: 527–533.
2009; 73: 1218–1226.
162. Scott AG, Austin HE. Nasogastric feeding in the man- 147. Jennings AL, Davies AN, Higgins JP, Gibbs JS, agement of severe dysphagia in motor neurone disease.
Broadley KE. A systematic review of the use of opioids Palliat Med 1994; 8: 45–49.
in the management of dyspnoea. Thorax 2002; 57: 939– 163. Verschueren A, Monnier A, Attarian S, Lardillier D, Pouget J. Enteral and parenteral nutrition in the later 148. Bruera E, Sweeney C, Willey J, et al. A randomized stages of ALS: an observational study. Amyotroph Lat- controlled trial of supplemental oxygen versus air in eral Scler 2009; 10: 42–46.
cancer patients with dyspnea. Palliat Med 2003; 17: 659– 164. Abelnour-Mallet M, Verschueren A, Guy N, et al. Safety of home parenteral nutrition in patients with amyo- 149. Winck JC, Gonc¸alves MR, Lourenc¸o C, Viana P, trophic lateral sclerosis: a French national survey.
Almeida J, Bach JR. Effects of mechanical insufﬂation- Amyotroph Lateral Scler 2010; 12: 178–184.
exsufﬂation on respiratory parameters for patients with 165. Gordon PH, Goetz RR, Rabkin JG, et al. A prospective chronic airway secretion encumbrance. Chest 2004; 126: cohort study of neuropsychological test performance in ALS. Amyotroph Lateral Scler 2010; 11: 312–320.
150. Lange DJ, Lechtzin N, Davey C, et al. High-frequency 166. Phukan J, Pender N, Hardiman O. Cognitive impair- chest wall oscillation in ALS: an exploratory random- ment in ALS. Lancet Neurol 2007; 6: 994–1003.
ized, controlled trial. Neurology 2006; 67: 991–997.
167. Elamin M, Phukan J, Bede P, et al. Executive dysfunc- 151. Marin B, Desport JC, Kajeu P, et al. Alteration of tion is a negative prognostic indicator in patients with nutritional status at diagnosis is a prognostic factor for ALS without dementia. Neurology 2011; 76: 1263–1269.
survival of amyotrophic lateral sclerosis patients. J Neu- 168. Ringholz GM, Appel SH, Bradshaw M, et al. Prevalence rol Neurosurg Psychiatry 2011; 82: 628–634.
and patterns of cognitive impairment in sporadic ALS.
152. Vaisman N, Lusaus M, Nefussy B, et al. Do patients Neurology 2005; 65: 586–590.
with amyotrophic lateral sclerosis (ALS) have increased 169. Strong MJ, Grace GM, Freedman M, et al. Consensus energy needs? J Neurol Sci 2009; 279: 26–29.
criteria for the diagnosis of frontotemporal cognitive and 153. Desport JC, Preux PM, Truong CT, Courat L, Vallat behavioural syndromes in amyotrophic lateral sclerosis.
JM, Couratier P. Nutritional assessment and survival in Amyotroph Lateral Scler 2009; 10: 131–146.
ALS patients. Amyotroph Lateral Scler Other Motor 170. Abrahams S, Leigh PN, Goldstein LH. Cognitive change Neuron Disord 2000; 1: 91–96.
in ALS: a prospective study. Neurology 2005; 64: 1222– 154. Heffernan C, Jenkinson C, Holmes T, et al. Nutritional management in MND/ALS patients: an evidence based 171. Gibbons ZC, Richardson A, Neary D, Snowden JS.
review. Amyotroph Lateral Scler Other Motor Neuron Behaviour in amyotrophic lateral sclerosis. Amyotroph Disord 2004; 5: 72–83.
Lateral Scler 2008; 9: 67–74.
Ó 2011 The Author(s) European Journal of Neurology Ó 2011 EFNS European Journal of Neurology P. M. Andersen et al.
172. Witgert M, Salamone AR, Strutt AM, et al. Frontal-lobe 179. Gordon PH, Wang Y, Doorish C, et al. A screening mediated behavioral dysfunction in amyotrophic lateral assessment of cognitive impairment in patients with sclerosis. Eur J Neurol 2010; 17: 103–110.
ALS. Amyotroph Lateral Scler 2007; 8: 362–365.
173. Gibbons ZC, Snowden JS, Thompson JC, Happe F, 180. Raaphorst J, De Visser M, Linssen WH, et al. The Richardson A, Neary D. Inferring thought and action in cognitive proﬁle of amyotrophic lateral sclerosis: a meta- motor neurone disease. Neuropsychologia 2007; 45: 1196– analysis. Amyotroph Lateral Scler 2010; 11: 27–37.
181. Bak TH, Hodges JR. Motor neurone disease, dementia 174. Girardi A, MacPherson SE, Abrahams S. Deﬁcits in and aphasia. Coincidence, co-occurrence or continuum.
Emotional and Social Cognition in Amyotrophic Lateral J Neurol 2001; 248: 260–270.
Sclerosis. Neuropsychology 2011; 25: 53–65.
182. Cobble M. Language impairment in motor neurone 175. Abrahams S, Goldstein LH, Suckling J, et al. Fronto- disease. J Neurol Sci 1998; 160(Suppl. 1): S47–S52.
temporal white matter changes in amyotrophic lateral 183. Borasio GD, Voltz R, Miller RG. Palliative care in sclerosis. J Neurol 2005; 252: 321–331.
amyotrophic lateral sclerosis. Neurol Clin 2001; 19: 829– 176. Donaghy C, Pinnock R, Abrahams S. Ocular ﬁxation instabilities in motor neurone disease. A marker 184. Mitsumoto H, Bromberg M, Johnston W, et al. Promot- of frontal lobe dysfunction? J Neurol 2009; 256: 420– ing excellence in end-of-life care in ALS. Amyotroph Lat- eral Scler Other Motor Neuron Disord 2005; 6: 145–154.
177. Flaherty-Craig C, Brothers A, Dearman B, Eslinger P, 185. Ganzini L, Johnston WS, McFarland BH, Tolle SW, Lee Simmons Z. Penn State screen exam for the detection of MA. Attitudes of patients with amyotrophic lateral frontal and temporal dysfunction syndromes: application sclerosis and their care givers toward assisted suicide.
to ALS. Amyotrop Lateral Scler 2009; 10: 107–112.
N Engl J Med 1998; 339: 967–973.
178. Woolley SC, York MK, Moore DH, et al. Detecting 186. Veldink JH, Wokke JH, van der Wal G, Vianney de Jong frontotemporal dysfunction in ALS: utility of the ALS JM, van den Berg LH. Euthanasia and physician-assisted Cognitive Behavioral Screen (ALS-CBSä). Amyotroph suicide among patients with amyotrophic lateral sclerosis Lateral Scler 2010; 11: 303–311.
in the Netherlands. N Engl J Med 2002; 346: 1638–1644.
Ó 2011 The Author(s)European Journal of Neurology Ó 2011 EFNS European Journal of Neurology
This is an author produced version of a paper published in Planta Medica This paper has been peer-reviewed but does not include the final publisher proof- corrections or journal pagination. Citation for the published paper: Endale, Milkyas; Alao, John Patrick; Akala, H. M.; Rono, N. K.; Eyase, F. L.; Derese, S.; Ndakala, A.; Mbugua, M.; Walsh, D. S.; Sunnerhagen, Per;